DE69329367T2 - Wachstumshormon-enthaltendeproteinformulierung - Google Patents

Wachstumshormon-enthaltendeproteinformulierung

Info

Publication number
DE69329367T2
DE69329367T2 DE69329367T DE69329367T DE69329367T2 DE 69329367 T2 DE69329367 T2 DE 69329367T2 DE 69329367 T DE69329367 T DE 69329367T DE 69329367 T DE69329367 T DE 69329367T DE 69329367 T2 DE69329367 T2 DE 69329367T2
Authority
DE
Germany
Prior art keywords
growth hormone
pct
formulation
citrate
buffer substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329367T
Other languages
English (en)
Other versions
DE69329367D1 (de
DE69329367T3 (de
Inventor
Staffan Castensson
Ebba Florin-Robertsson
Elvy Hoekby
Sirkka Thome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20385860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69329367(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of DE69329367D1 publication Critical patent/DE69329367D1/de
Publication of DE69329367T2 publication Critical patent/DE69329367T2/de
Application granted granted Critical
Publication of DE69329367T3 publication Critical patent/DE69329367T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69329367T 1992-04-03 1993-04-01 Wachstumshormon-enthaltende proteinformulierung Expired - Fee Related DE69329367T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9201073A SE9201073D0 (sv) 1992-04-03 1992-04-03 Protein formulation
SE9201073 1992-04-03
PCT/SE1993/000281 WO1993019776A1 (en) 1992-04-03 1993-04-01 Protein formulation comprising growth hormone

Publications (3)

Publication Number Publication Date
DE69329367D1 DE69329367D1 (de) 2000-10-12
DE69329367T2 true DE69329367T2 (de) 2001-06-21
DE69329367T3 DE69329367T3 (de) 2008-06-19

Family

ID=20385860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329367T Expired - Fee Related DE69329367T3 (de) 1992-04-03 1993-04-01 Wachstumshormon-enthaltende proteinformulierung

Country Status (15)

Country Link
US (1) US5567677A (de)
EP (1) EP0587858B2 (de)
JP (1) JP3268557B2 (de)
AT (1) ATE196092T1 (de)
AU (1) AU666007B2 (de)
CA (1) CA2102693C (de)
DE (1) DE69329367T3 (de)
DK (1) DK0587858T3 (de)
ES (1) ES2150940T5 (de)
GR (1) GR3034925T3 (de)
NO (1) NO310804B1 (de)
NZ (1) NZ251498A (de)
PT (1) PT587858E (de)
SE (1) SE9201073D0 (de)
WO (1) WO1993019776A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
ZA9711733B (en) 1996-12-31 1998-07-01 Monsanto Co Method for solubilization and naturation of somatotropins
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
CZ200260A3 (cs) * 1999-07-12 2002-04-17 Grandis Biotech Gmbh Formulace růstového hormonu
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
CA2491478A1 (en) * 2002-07-09 2004-01-15 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20060252682A1 (en) * 2003-03-18 2006-11-09 Ares Trading S.A. Liquid growth hormone formulation and process of preparation thereof
CA2551510C (en) 2003-12-23 2013-07-30 Pharmacia Corporation Stable growth hormone liquid formulation
DK1740213T3 (da) * 2004-04-07 2012-04-10 Ares Trading Sa Væskeformulering til væksthormoner
WO2006017643A1 (en) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Rage fusion proteins and methods of use
GEP20105110B (en) * 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
KR101149454B1 (ko) * 2004-08-24 2012-05-25 간가와 겐지 생리활성 펩티드의 액상 제제
EP1809663B1 (de) * 2004-11-09 2008-09-17 Ares Trading S.A. Verfahren zur reinigung von fsh
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EA015901B1 (ru) 2005-08-26 2011-12-30 Арес Трейдинг С.А. Способ получения гликозилированного интерферона бета
WO2007056105A2 (en) * 2005-11-02 2007-05-18 Transpharma Medical Ltd. Human growth hormone patch formulations
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
US7957931B2 (en) * 2005-12-23 2011-06-07 Gcoder Systems Ab Positioning pattern
US20090004190A1 (en) * 2006-02-09 2009-01-01 Mjalli Adnan M M Rage Fusion Proteins And Methods Of Use
EP2380983A3 (de) * 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE-Fusionsproteine, Formulierungen daraus und Verfahren zu ihrer Verwendung
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
JP2011500757A (ja) * 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製方法
EP2203474A1 (de) * 2007-10-22 2010-07-07 Merck Serono S.A. Verfahren zur reinigung von fc-fusionsproteinen
CA2757079C (en) 2009-04-20 2015-05-19 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
US20120108512A1 (en) * 2009-05-07 2012-05-03 Novo Nordisk Health Care Ag Stable pharmaceutical compositions of peptide derivatized using an oxime linker
CA2780554C (en) * 2009-11-17 2017-08-15 Ipsen Pharma S.A.S. Formulation for hgh and rhigf-1 combination
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN105848645A (zh) * 2013-09-27 2016-08-10 韩美药品株式会社 持续型人生长激素制剂
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
EP0189673B1 (de) * 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stabiles GRF-Präparat
BR8603586A (pt) * 1985-07-30 1987-03-10 Int Minerals & Chem Corp Processo para manter a fluidez de um homonio;processo para efetuar a promocao de crescimento em animais e formulacao promotora de crescimento
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0303746B2 (de) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisierung von Wachstumshormonen
US4837202A (en) † 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
WO1994003198A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH01308235A (ja) * 1988-06-03 1989-12-12 Yamanouchi Pharmaceut Co Ltd ヒト成長ホルモン経鼻剤
US5008244A (en) * 1989-05-15 1991-04-16 Pitman-Moore, Inc. Method for increasing fertility in animals
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
IN172427B (de) * 1989-11-14 1993-07-24 Fidia Spa
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
ATE173739T1 (de) † 1992-04-30 1998-12-15 Cor Therapeutics Inc Stabile zusammensetzung von polypeptiden

Also Published As

Publication number Publication date
GR3034925T3 (en) 2001-02-28
JP3268557B2 (ja) 2002-03-25
ES2150940T3 (es) 2000-12-16
JPH06508156A (ja) 1994-09-14
EP0587858A1 (de) 1994-03-23
AU666007B2 (en) 1996-01-25
DE69329367D1 (de) 2000-10-12
PT587858E (pt) 2001-02-28
NO934355D0 (no) 1993-11-30
DE69329367T3 (de) 2008-06-19
DK0587858T3 (da) 2000-12-18
EP0587858B1 (de) 2000-09-06
NZ251498A (en) 1995-07-26
EP0587858B2 (de) 2007-11-14
CA2102693C (en) 2008-06-17
SE9201073D0 (sv) 1992-04-03
NO934355L (no) 1993-12-01
AU3913593A (en) 1993-11-08
ATE196092T1 (de) 2000-09-15
CA2102693A1 (en) 1993-10-04
NO310804B1 (no) 2001-09-03
ES2150940T5 (es) 2008-04-16
US5567677A (en) 1996-10-22
WO1993019776A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
ATE196092T1 (de) Wachstumshormon-enthaltendeproteinformulierung
CA2275890A1 (en) Stable liquid interferon formulations
ATE255450T1 (de) Matrix für iontophorese
ATE175424T1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
IL135186A0 (en) LIQUID INTERFERON-β FORMULATIONS
PL274485A1 (en) Method of obtaining stable preparations of human proteins
DE3585556D1 (de) Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
DE69715414D1 (de) Stabilisierte pharmazeutische zusammensetzung von bdnf
DK1044015T3 (da) Formuleringer med amylinagonistpeptider og insulin
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
Li Recent studies on the problems involved in the preparation, properties and bioassay of adrenocorticotrophic hormone
Holbrook et al. The identification of a peptide in human parotid saliva particularly active in enhancing the glycolytic activity of the salivary micro-organisms.
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
Donohue Jr et al. Glucose-6-phosphate dehydrogenase Partial characterization of the rat liver and uterine enzymes
Leaver Studies on certain peptide fractions isolated from human dentine
Lafeber Comparison of PTH and hypocalcin in mammalian and teleost bioassays

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA AB, STOCKHOLM, SE

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER HEALTH AB, STOCKHOLM, SE

8339 Ceased/non-payment of the annual fee